deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02257541

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Sponsor: Dana-Farber Cancer Institute

Conditions Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions BGJ398 Imatinib Mesylate
Updated 13 times since 2017 Last updated: Mar 16, 2020 Started: Oct 2, 2014 Primary completion: Mar 25, 2019 Completion: Mar 25, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02257541, this PHASE1/PHASE2 trial focuses on Advanced Gastrointestinal Stromal Tumor (GIST) and remains completed. Sponsored by Dana-Farber Cancer Institute, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Apr 2019 — Apr 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Nov 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. May 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • University of Pittsburgh
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations